---
title: Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)
nct_id: NCT01569373
overall_status: WITHDRAWN
sponsor: Mayo Clinic
study_type: OBSERVATIONAL
primary_condition: Blood Stem Cell Transplant Failure
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01569373.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01569373"
ct_last_update_post_date: 2023-09-29
last_seen_at: "2026-05-12T06:19:16.413Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)

**Official Title:** Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD).

**NCT ID:** [NCT01569373](https://clinicaltrials.gov/study/NCT01569373)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Resources needed to complete the study were not able to be obtained.
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** Mayo Clinic
- **Conditions:** Blood Stem Cell Transplant Failure
- **Start Date:** 2012-03
- **Completion Date:** 2017-10
- **CT.gov Last Update:** 2023-09-29

## Brief Summary

Samples of blood and urine will be analyzed for biomarkers to check their predictivity of Graft-versus-Host Disease (GVHD) outcomes.

## Detailed Description

To determine if serum biomarkers of inflammation correlate with onset and severity of acute GVHD, particularly GVHD of the gut.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years old or older patients
* Undergoing allogeneic stem cell transplant

Exclusion Criteria:

None
```

## Arms

- **Post allogeneic SCT patients** — Patients who have undergone an allogeneic stem cell transplant.

## Primary Outcomes

- **Diagnosis of severe acute GVHD** _(time frame: 2 months)_

## Locations (1)

- Mayo Clinic, Rochester, Minnesota, United States

## Recent Field Changes (last 30 days)

- `eligibility.criteria` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.mayo clinic|rochester|minnesota|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01569373.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01569373*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*